Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Global experience with new extended-depth-of-focus intraocular lens

Search Title by author or title

Session Details

Session Title: Pseudophakic IOLs: Enlarged-Depth-of-Focus II

Session Date/Time: Monday 12/09/2016 | 16:00-18:00

Paper Time: 16:06

Venue: Hall C3

First Author: : J.Vukich USA

Co Author(s): :                        

Abstract Details

Purpose:

To demonstrate visual performance and patient satisfaction with contralateral implantation of an aspheric monofocal IOL in the dominant eye and an extended depth of focus intraocular lens in the non-dominant eye.

Setting:

Multiple clinics throughout the world.

Methods:

Prospective, multicenter, open-label clinical study. 102 patients have been implanted and three-month outcomes are presented on 63 patients. Binocular uncorrected distance, intermediate and near visual acuities (UDVA, UIVA & UNVA) and patient satisfaction were evaluated. Mean ± standard deviation visual acuity is reported in logMAR. Interim results are presented here and additional patients and longer-term follow up data will be presented.

Results:

The mean binocular UDVA, UIVA and UNVA were -0.03 ± 0.14 (20/18), 0.03 ± 0.10 (20/21) and 0.17 ± 0.11 (20/29) at 3 months. At 3 months, 100%, 100% and 95.3% of patients achieved 20/40 or better binocularly at distance, intermediate and near respectively. 96.7% of patients said they would do the procedure again. Overall the average rating for glare and halos were 1.5 ± 1.1 and 1.1 ± 1.5 out of a maximum rating of 5 (very severe).

Conclusions:

Contralateral implantation of the small aperture IC-8 IOL and aspheric monofocal IOL shows excellent visual performance and patient satisfaction at three-months following implantation.

Financial Disclosure:

... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to previous